

Karine Andrieux

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3354556/publications.pdf>

Version: 2024-02-01

59
papers

3,457
citations

218677

26
h-index

138484

58
g-index

63
all docs

63
docs citations

63
times ranked

4993
citing authors

#	ARTICLE	IF	CITATIONS
1	Mixed Polymeric Micelles for Rapamycin Skin Delivery. <i>Pharmaceutics</i> , 2022, 14, 569.	4.5	9
2	How Could Nanomedicine Improve the Safety of Contrast Agents for MRI during Pregnancy?. <i>Sci</i> , 2022, 4, 11.	3.0	3
3	Placental Models for Evaluation of Nanocarriers as Drug Delivery Systems for Pregnancy Associated Disorders. <i>Biomedicines</i> , 2022, 10, 936.	3.2	7
4	Influence of Liposomes [™] and Lipoplexes [™] Physicochemical Characteristics on Their Uptake Rate and Mechanisms by the Placenta. <i>International Journal of Molecular Sciences</i> , 2022, 23, 6299.	4.1	2
5	Dermatillomania: Strategies for Developing Protective Biomaterials/Cloth. <i>Pharmaceutics</i> , 2021, 13, 341.	4.5	5
6	Cationic lipid nanoparticle production by microfluidization for siRNA delivery. <i>International Journal of Pharmaceutics</i> , 2021, 605, 120772.	5.2	7
7	Long-term stability of 0.1% rapamycin hydrophilic gel in the treatment of facial angiofibromas. <i>European Journal of Hospital Pharmacy</i> , 2020, 27, e48-e52.	1.1	11
8	Comparison of the In Vitro and Ex Vivo Permeation of Existing Topical Formulations Used in the Treatment of Facial Angiofibroma and Characterization of the Variations Observed. <i>Pharmaceutics</i> , 2020, 12, 1060.	4.5	13
9	Qualitative and quantitative analysis of the uptake of lipoplexes by villous placenta explants. <i>International Journal of Pharmaceutics</i> , 2019, 567, 118479.	5.2	8
10	Nanomedicine as a potential approach to empower the new strategies for the treatment of preeclampsia. <i>Drug Discovery Today</i> , 2018, 23, 1099-1107.	6.4	27
11	Intravenous infusion for the controlled exposure to the dual ABCB1 and ABCG2 inhibitor elacridar in nonhuman primates. <i>Drug Delivery and Translational Research</i> , 2018, 8, 536-542.	5.8	7
12	Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer's disease-like transgenic mouse model. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 609-618.	3.3	109
13	Liposomes as Gene Delivery Vectors for Human Placental Cells. <i>Molecules</i> , 2018, 23, 1085.	3.8	20
14	Assessment of dually labelled PEGylated liposomes transplacental passage and placental penetration using a combination of two ex-vivo human models: the dually perfused placenta and the suspended villous explants. <i>International Journal of Pharmaceutics</i> , 2017, 532, 729-737.	5.2	23
15	Application of Nanomedicine to the CNS Diseases. <i>International Review of Neurobiology</i> , 2016, 130, 73-113.	2.0	17
16	Pharmacokinetics, biodistribution and metabolism of squalenoyl adenosine nanoparticles in mice using dual radio-labeling and radio-HPLC analysis. <i>Journal of Controlled Release</i> , 2015, 212, 50-58.	9.9	22
17	Transport Mechanisms of Squalenoyl-Adenosine Nanoparticles Across the Blood-Brain Barrier. <i>Chemistry of Materials</i> , 2015, 27, 3636-3647.	6.7	32
18	Nanomedicines and stroke: Toward translational research. <i>Journal of Drug Delivery Science and Technology</i> , 2015, 30, 278-299.	3.0	12

#	ARTICLE	IF	CITATIONS
19	Systemically Administered Brain-Targeted Nanoparticles Transport Peptides across the Blood-Brain Barrier and Provide Neuroprotection. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2015, 35, 469-475.	4.3	97
20	Squalenoyl adenosine nanoparticles provide neuroprotection after stroke and spinal cord injury. <i>Nature Nanotechnology</i> , 2014, 9, 1054-1062.	31.5	207
21	Anti-HIV efficacy and biodistribution of nucleoside reverse transcriptase inhibitors delivered as squalenoylated prodrug nanoassemblies. <i>Biomaterials</i> , 2013, 34, 4831-4838.	11.4	31
22	Effect of nanoparticles binding β -amyloid peptide on nitric oxide production by cultured endothelial cells and macrophages. <i>International Journal of Nanomedicine</i> , 2013, 8, 1335.	6.7	11
23	PEGylated Nanoparticles Bind to and Alter Amyloid-Beta Peptide Conformation: Toward Engineering of Functional Nanomedicines for Alzheimer's Disease. <i>ACS Nano</i> , 2012, 6, 5897-5908.	14.6	164
24	Versatile and Efficient Targeting Using a Single Nanoparticulate Platform: Application to Cancer and Alzheimer's Disease. <i>ACS Nano</i> , 2012, 6, 5866-5879.	14.6	127
25	Quantum dot-loaded PEGylated poly(alkyl cyanoacrylate) nanoparticles for in vitro and in vivo imaging. <i>Soft Matter</i> , 2011, 7, 6187.	2.7	23
26	Colloidal properties of biodegradable nanoparticles influence interaction with amyloid- β peptide. <i>Journal of Biotechnology</i> , 2011, 156, 338-340.	3.8	19
27	Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2011, 7, 521-540.	3.3	240
28	Selegiline-functionalized, PEGylated poly(alkyl cyanoacrylate) nanoparticles: Investigation of interaction with amyloid- β peptide and surface reorganization. <i>International Journal of Pharmaceutics</i> , 2011, 416, 453-460.	5.2	25
29	A new nanomedicine based on didanosine glycerolipidic prodrug enhances the long term accumulation of drug in a HIV sanctuary. <i>International Journal of Pharmaceutics</i> , 2011, 414, 285-297.	5.2	16
30	Nanoparticles against Alzheimer's disease: PEG-PACA nanoparticles are able to link the $\alpha\beta$ -peptide and influence its aggregation kinetic. <i>Journal of Controlled Release</i> , 2010, 148, e112-e113.	9.9	12
31	Nanoparticles against Alzheimer's disease: PEG-PACA Nanoparticles are able to link the $A\beta$ -peptide and influence its aggregation kinetic. <i>Journal of Biotechnology</i> , 2010, 150, 27-27.	3.8	2
32	New Method Based on Capillary Electrophoresis with Laser-Induced Fluorescence Detection (CE-LIF) to Monitor Interaction between Nanoparticles and the Amyloid- β Peptide. <i>Analytical Chemistry</i> , 2010, 82, 10083-10089.	6.5	50
33	Design of fluorescently tagged poly(alkyl cyanoacrylate) nanoparticles for human brain endothelial cell imaging. <i>Chemical Communications</i> , 2010, 46, 2602.	4.1	44
34	Formulation of glycerolipidic prodrugs into PEGylated liposomes for brain delivery. <i>Journal of Drug Delivery Science and Technology</i> , 2009, 19, 61-66.	3.0	2
35	Strategies to Increase the Oral Bioavailability of Nucleoside Analogs. <i>Current Medicinal Chemistry</i> , 2009, 16, 1391-1399.	2.4	14
36	Application of thermal analysis to the study of lipidic prodrug incorporation into nanocarriers. <i>Journal of Thermal Analysis and Calorimetry</i> , 2009, 98, 65-71.	3.6	7

#	ARTICLE	IF	CITATIONS
37	Polyalkylcyanoacrylate nanoparticles for delivery of drugs across the blood-brain barrier. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2009, 1, 463-474.	6.1	71
38	Metabolism evaluation of biomimetic prodrugs by in vitro models and mass spectrometry. International Journal of Pharmaceutics, 2009, 379, 235-243.	5.2	16
39	A Nanomedicine Transports a Peptide Caspase-3 Inhibitor across the Blood-Brain Barrier and Provides Neuroprotection. Journal of Neuroscience, 2009, 29, 13761-13769.	3.6	169
40	Solubilisation of dipalmitoylphosphatidylcholine bilayers by sodium taurocholate: A model to study the stability of liposomes in the gastrointestinal tract and their mechanism of interaction with a model bile salt. European Journal of Pharmaceutics and Biopharmaceutics, 2009, 71, 346-355.	4.3	70
41	Colloidal Carriers: A Promising Way to Treat Central Nervous System Diseases. Journal of Nanoneuroscience, 2009, 1, 17-34.	0.5	9
42	Formulation of Didanosine Prodrugs into PEGylated Poly(alkyl cyanoacrylate) Nanoparticles and Uptake by Brain Endothelial Cells. Journal of Nanoneuroscience, 2009, 1, 174-183.	0.5	3
43	Synthesis of Highly Functionalized Poly(alkyl cyanoacrylate) Nanoparticles by Means of Click Chemistry. Macromolecules, 2008, 41, 8418-8428.	4.8	40
44	Translocation of Poly(ethylene glycol-co-hexadecyl)cyanoacrylate Nanoparticles into Rat Brain Endothelial Cells: A Role of Apolipoproteins in Receptor-Mediated Endocytosis. Biomacromolecules, 2007, 8, 793-799.	5.4	172
45	Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2-DE, CE and Protein Lab-on-chip system. Electrophoresis, 2007, 28, 2252-2261.	2.4	135
46	Synthesis and biological evaluation of two glycerolipidic prodrugs of didanosine for direct lymphatic delivery against HIV. Bioorganic and Medicinal Chemistry Letters, 2007, 17, 2237-2240.	2.2	33
47	Liposomal formulation of a glycerolipidic prodrug for lymphatic delivery of didanosine via oral route. International Journal of Pharmaceutics, 2007, 344, 62-70.	5.2	26
48	Low-density lipoprotein receptor-mediated endocytosis of PEGylated nanoparticles in rat brain endothelial cells. Cellular and Molecular Life Sciences, 2007, 64, 356-364.	5.4	157
49	Nanotechnologies for drug delivery: Application to cancer and autoimmune diseases. Progress in Solid State Chemistry, 2006, 34, 231-235.	7.2	75
50	Preparation and in vitro evaluation of chitosan nanoparticles containing a caspase inhibitor. International Journal of Pharmaceutics, 2005, 298, 378-383.	5.2	118
51	A methodology to study intracellular distribution of nanoparticles in brain endothelial cells. International Journal of Pharmaceutics, 2005, 298, 310-314.	5.2	60
52	Colloidal carriers and blood-brain barrier (BBB) translocation: A way to deliver drugs to the brain?. International Journal of Pharmaceutics, 2005, 298, 274-292.	5.2	289
53	A relevant in vitro rat model for the evaluation of blood-brain barrier translocation of nanoparticles. Cellular and Molecular Life Sciences, 2005, 62, 1400-1408.	5.4	97
54	Development and Brain Delivery of Chitosan-PEG Nanoparticles Functionalized with the Monoclonal Antibody OX26. Bioconjugate Chemistry, 2005, 16, 1503-1511.	3.6	279

#	ARTICLE	IF	CITATIONS
55	Insertion and Partition of Sodium Taurocholate into Egg Phosphatidylcholine Vesicles. <i>Pharmaceutical Research</i> , 2004, 21, 1505-1516.	3.5	26
56	Intraocular injection of tamoxifen-loaded nanoparticles: a new treatment of experimental autoimmune uveoretinitis. <i>European Journal of Immunology</i> , 2004, 34, 3702-3712.	2.9	128
57	Characterization of Fluorescein Isothiocyanate-Dextran Used in Vesicle Permeability Studies. <i>Analytical Chemistry</i> , 2002, 74, 5217-5226.	6.5	30
58	Methodology for vesicle permeability study by high-performance gel exclusion chromatography. <i>Biomedical Applications</i> , 1998, 706, 141-147.	1.7	12
59	Analysis of Serum Proteins by Micellar Electrokinetic Capillary Chromatography. Application to a Drug Carrier Evaluation. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1996, 19, 3333-3353.	1.0	8